Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
31 janv. 2023 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
07 déc. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
28 nov. 2022 06h35 HE
|
Axsome Therapeutics, Inc.
AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of...
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
23 nov. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
09 nov. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
07 nov. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
Sunosi® third quarter U.S. net sales of $16.8 million Auvelity™ launched and available in U.S. pharmacies SHARP study results announced demonstrating statistically significant improvement in...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
27 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
21 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
20 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 ...
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
10 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...